AceLink Therapeutics, Inc., a clinical-stage biotech company developing next-generation oral substrate reduction therapies (SRTs), presented interim d ...

As part of The Wistar Institute's Melanoma Research Center, the Villanueva lab pursues new ways to overcome the challenge of melanoma drug resistance. In this paper, the group took aim at melanomas ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

Objective To determine whether new users of proton pump inhibitors (PPIs) are at an increased risk of gastric cancer compared with new users of histamine-2 receptor antagonists (H2RAs). Design Using ...

Minerva Author is an authoring tool used to create Minerva narrated stories via selection of specific channel groupings and image views.

Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much ...

1 Department of Hepatology, Center of Infectious Diseases and Pathogen Biology, The First Hospital of Jilin University, Changchun, Jilin, China 2 Key Laboratory of Zoonosis Research, Ministry of ...

Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much higher ...

Please provide your email address to receive an email when new articles are posted on . GLP-1 receptor agonists reduced the risk for dozens of possible adverse health outcomes. However, many ...

SGLT2 inhibitor use might be renoprotective in patients with ADPKD, but could increase kidney volume. Dapagliflozin might help protect kidney function in patients with autosomal dominant polycystic ...

Objective Sodium–glucose cotransporter 2 (SGLT-2) inhibitors are the most recently approved antihyperglycemic medications. We sought to describe their association with euglycemic diabetic ...